Accessibility Menu
 
Mineralys Therapeutics logo

Mineralys Therapeutics

(NASDAQ) MLYS

Current Price$27.28
Market Cap$2.41B
Since IPO (2023)+60%
5 YearN/A
1 Year+95%
1 Month+10%

Mineralys Therapeutics Financials at a Glance

Market Cap

$2.41B

Revenue (TTM)

$0.00

Net Income (TTM)

$151.78M

EPS (TTM)

$-2.06

P/E Ratio

-14.21

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$27.28

Volume

683,595.248

Open

$29.00

Previous Close

$29.26

Daily Range

$26.71 - $29.11

52-Week Range

$12.59 - $47.65

MLYS: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mineralys Therapeutics

Industry

Biotechnology

Employees

76

CEO

Jon Congleton

Headquarters

Radnor, PA 19087, US

MLYS Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-31%

Return on Capital

-27%

Return on Assets

-23%

Earnings Yield

-7.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.41B

Shares Outstanding

82.50M

Volume

683.60K

Avg. Volume

1.20M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$170.60M

EBITDA

$170.54M

Operating Cash Flow

$142.42M

Capital Expenditure

$15.00K

Free Cash Flow

$142.43M

Cash & ST Invst.

$656.63M

Total Debt

$0.00

Mineralys Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$6.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.41B

N/A

Market Cap/Employee

$47.33M

N/A

Employees

51

N/A

Net Income

$39.34M

+6.8%

EBITDA

$45.34M

-2.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$646.06M

+88.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-23.25%

N/A

Return on Invested Capital

-26.87%

N/A

Free Cash Flow

$39.47M

+13.2%

Operating Cash Flow

$39.47M

+13.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IDYAIDEAYA Biosciences, Inc.
$28.33+0.75%
ZLABZai Lab Limited
$19.90+1.89%
ADPTAdaptive Biotechnologies Corporation
$13.27-2.62%
AGIOAgios Pharmaceuticals, Inc.
$28.48+0.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$17.07+0.07%
EOSEEos Energy Enterprises
$8.94+0.10%
NOKNokia
$14.19+0.08%
VNETVnet Group
$11.34+0.26%

Questions About MLYS

What is the current price of Mineralys Therapeutics?

Mineralys Therapeutics is trading at $27.35 per share.

What is the 52-week range for Mineralys Therapeutics?

Over the past 52 weeks, Mineralys Therapeutics has traded between $12.59 and $47.65.

How much debt does Mineralys Therapeutics have?

As of the most recent reporting period, Mineralys Therapeutics reported total debt of N/A.

How much cash does Mineralys Therapeutics have on hand?

Mineralys Therapeutics reported $112.78M in cash and cash equivalents in its most recent financial results.

What is Mineralys Therapeutics’s dividend yield?

Mineralys Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.